tbuckley/cabot-search huggingface dataset:
Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials
Authors: Joseph M. Unger, Anna B. Moseley, Christabel K. Cheung, Raymond U. Osarogiagbon, Banu Symington, Scott D. Ramsey, Dawn L. Hershman
Journal: Journal of Clinical Oncology (2021)

PURPOSE Patients with cancer living in socioeconomically disadvantaged areas have worse cancer outcomes. The association between socioeconomic deprivation and outcomes among patients with cancer participating in clinical trials has not been systematically examined. METHODS We examined survival outcomes for patients enrolled in phase III and large phase II clinical trials for major cancers conducted by the SWOG Cancer Research Network from 1985 to 2012. Socioeconomic deprivation was measured using trial participants' residential zip codes linked to the Area Deprivation Index (ADI). Five-year overall survival, progression-free survival, and cancer-specific survival were examined using Cox regression frailty models, adjusting for age, sex, and race, and separately for insurance status, prognostic risk, and rural or urban residency. RESULTS We examined 41,109 patients from 55 trials comprising 24 cancer histology and stage-specific cohorts. Compared with trial participants in the most affluent areas (ADI, 0%-20%), trial participants from areas with the highest socioeconomic deprivation (ADI, 80%-100%) had worse overall (hazard ratio [HR] = 1.28, 95% CI, 1.20 to 1.37, P &lt; .001), progression-free (HR = 1.20, 95% CI, 1.13 to 1.28, P &lt; .001), and cancer-specific survival (HR = 1.27, 95% CI, 1.18 to 1.37, P &lt; .001). The results were similar after adjusting for insurance status, prognostic risk, and rural or urban residency. There was a continuous increase in risk of all outcomes as the ADI quintile increased. CONCLUSION In patients with cancer with access to protocol-directed care in clinical trials, high area-level socioeconomic deprivation was associated with worse survival. Future research should examine whether the etiology of this residual disparity is related to reduced access to supportive care or postprotocol therapy and/or to differences in health status not reflected by protocol selection criteria.
P72.10 Prognostic Significance of IgA+ B Cells in Non-Small Cell Lung Cancer
Authors: M. Vanderputten, F. Aboubakar, C. Bouzin, D. Hoton, C. Stanciu Pop, M. Lecocq, J. Ambroise, C. Pilette, S. Ocak
Journal: Journal of Thoracic Oncology (2021)
P09.06 CNS Metastasis Negatively Impact Overall Survival of Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors
Authors: C. Souza, M.D. Spina Donadio, M.F. Simões, D. Maciel Santana, M.F. Barbosa De Medeiros, L.B. Mendes Gomes, M. Petrocchi Corassa, H. De Freitas, V.C. De Lima
Journal: Journal of Thoracic Oncology (2021)
P78.08 Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland
Authors: M. Knetki-Wróblewska, D.M. Kowalski, A. Pluzanski, O. Stanowska, P. Wisniewski, K. Winiarczyk, M. Zaborowska-Szmit, K. Zajda, M. Prochorec-Sobieszek, M. Krzakowski
Journal: Journal of Thoracic Oncology (2021)
Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers
Authors: Ross J. Harris, Heather J. Whitaker, Nick J. Andrews, Felicity Aiano, Zahin Amin-Chowdhury, Jessica Flood, Ray Borrow, Ezra Linley, Shazaad Ahmad, Lorraine Stapley, Bassam Hallis, Gayatri Amirthalingam, Katja Höschler, Ben Parker, Alex Horsley, Timothy J.G. Brooks, Kevin E. Brown, Mary E. Ramsay, Shamez N. Ladhani
Journal: Journal of Infection (2021)
Viral infection modulates Qa-1b in infected and bystander cells to properly direct NK cell killing
Authors: Maria Ferez, Cory J. Knudson, Avital Lev, Eric B. Wong, Pedro Alves-Peixoto, Lingjuan Tang, Colby Stotesbury, Luis J. Sigal
Journal: The Journal of Experimental Medicine (2021)

Natural killer (NK) cell activation depends on the signaling balance of activating and inhibitory receptors. CD94 forms inhibitory receptors with NKG2A and activating receptors with NKG2E or NKG2C. We previously demonstrated that CD94-NKG2 on NK cells and its ligand Qa-1b are important for the resistance of C57BL/6 mice to lethal ectromelia virus (ECTV) infection. We now show that NKG2C or NKG2E deficiency does not increase susceptibility to lethal ECTV infection, but overexpression of Qa-1b in infected cells does. We also demonstrate that Qa-1b is down-regulated in infected and up-regulated in bystander inflammatory monocytes and B cells. Moreover, NK cells activated by ECTV infection kill Qa-1b–deficient cells in vitro and in vivo. Thus, during viral infection, recognition of Qa-1b by activating CD94/NKG2 receptors is not critical. Instead, the levels of Qa-1b expression are down-regulated in infected cells but increased in some bystander immune cells to respectively promote or inhibit their killing by activated NK cells.
P62.10 Rhophilin-2 Upregulates Glutamine Synthetase by Stabilizing c-Myc Protein and Confers Resistance to Glutamine Deprivation in Lung Cancer
Authors: Z. Guo, D. Xiao, J. He, H. He, S. Yang, L. Huang, H. Pan, J. He
Journal: Journal of Thoracic Oncology (2021)
P33.12 Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study
Authors: D. Lin, X. Yang, L. Jiang, W. Wang, Y. Hou, Y. Li, Y. Jin, X. Fan, W. Sun, J. Yun, P. Li, D. Kuang, L. Zhang, J. Ni, A. Mao, W. Tang, Z. Liu, J. Wang, S. Xiao
Journal: Journal of Thoracic Oncology (2021)
MA05.05 Low-Dose Chest Computed Tomographic Screening and Invasive Diagnosis of Pulmonary Nodules for Lung Cancer in Never-Smokers
Authors: Y.W. Kim, H. Kang, B.S. Kwon, S.Y. Lim, Y.J. Lee, J.S. Park, Y. Cho, H.I. Yoon, K.W. Lee, J.H. Lee, C. Lee
Journal: Journal of Thoracic Oncology (2021)
Abstract 10377: Constitutive Adiponectin Administration Using Adipocyte Sheet-Based Drug Delivery System Ameliorates Cardiac Dysfunction in Mouse Myocardial Infarction Model
Authors: Yukiko Imanishi, Shigeru Miyagawa, Norikazu Maeda, Iichiro Shimomura, Yoshiki Sawa
Journal: Circulation (2010)

Background: The adipocyte derived cytokine adiponectin (APN) has beneficial effects for cardiovascular diseases. However, APN targeted delivery to distressed myocardium in a constitutive manner is ...
P79.07 Comparative Efficacy and Safety of PD-(L)1 Inhibitors Combined with 1st-Line Chemotherapy for Advanced NSCLC: A Meta-Analysis
Authors: A. Di Federico, A. De Giglio, C. Parisi, F. Gelsomino, L. Boni, A. Ardizzoni
Journal: Journal of Thoracic Oncology (2021)
0.5mmスライスのコンピュータ断層撮影画像によるアテローム硬化性プラークの評価を,脈管内超音波と比較した
Authors: Motoyama Sadako, Kondo Takeshi, Anno Hirofumi, Sugiura Atsushi, Ito Yoshihiro, Mori Kazumasa, Ishii Junichi, Sato Takahisa, Inoue Kaori, Sarai Masayoshi, Hishida Hitoshi, Narula Jagat
Journal: Circulation (2007)
Abstract 19967: Differential Roles of the NADPH-Oxidase 1 and 2 in Platelet Activation and Thrombosis
Authors: Michael K Delaney, Kyungho Kim, Brian Estevez, Aleksandra Stojanovic-Terpo, Bo Shen, Masuko Ushio-Fukai, Jaehyung Cho, Xiaoping Du
Journal: Circulation (2015)

Objective: Reactive oxygen species (ROS) generated from activated platelets is known to regulate platelet activation. However, it remains unclear whether and how different isoforms of nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidases (NOXs) play roles in different platelet activation pathways. Here we investigated the role of NOX1 and NOX2 in different platelet activation pathways using NOX1 and NOX2 knockout mice. Approach and Results: NOX1-/- platelets showed selective defects in G protein coupled receptor (GPCR)-mediated platelet activation induced by thrombin, protease-activated receptor 4 agonist peptide (PAR4AP) and thromboxane A2 analog U46619, but was not affected in platelet activation induced by collagen-related peptide (CRP), a glycoprotein VI (GPVI) agonist. In contrast, NOX2-/- platelets showed potent inhibition of CRP-induced platelet activation, and also showed partial inhibition of thrombin-induced platelet aggregation and secretion. Consistently, production of reactive oxygen species (ROS) was inhibited in NOX1-/- platelets stimulated with thrombin, but not CRP, whereas NOX2-/- platelets showed reduced ROS generation induced by CRP or thrombin. Interestingly, laser-induced arterial thrombosis was impaired in NOX2-/- mice, and in thrombocytopenic mice transfused with NOX2-/- platelets, suggesting an important role for NOX2-dependent platelet ROS production in the laser-induced injury model of thrombosis. Conclusions: NOX1 and NOX2 play differential roles in different platelet activation pathways: NOX1 mediates GPCR-mediated ROS production and platelet activation, whereas NOX2 plays a general role in GPVI- and GPCR-induced ROS production and platelet activation in vitro , and in laser-induced thrombosis in vivo .
P20.02 To Evaluate the Efficacy and Optimal Timing of Postoperative Radiotherapy in Completely Resected stage IIIA(N2) Non-Small Cell Lung Cancer
Authors: W. Feng, X. Fu, X. Cai, J. Liu, D. Hu, Y. Xu, Z. Zhu, S. Zhao, Y. Bai, J. He, T. Chen
Journal: Journal of Thoracic Oncology (2021)
Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform
Authors: Sakiko Suzuki, Ronny R Racine, Nathan A Manalo, Neeraj Saini, Cliff Odour, Michael Moazami, Jeffrey A Bailey, Jonathan K Watts, Glen D. Raffel
Journal: Blood (2017)
The subcellular redistribution of NLRC5 promotes angiogenesis via interacting with STAT3 in endothelial cells
Authors: Xu Xu, Yefei Shi, Peipei Luan, Wenxin Kou, Bo Li, Ming Zhai, Shuangjie You, Qing Yu, Jianhui Zhuang, Weixia Jian, Mark W. Feinberg, Wenhui Peng
Journal: Theranostics (2021)

Angiogenesis is a critical step in repair of tissue injury. The pattern recognition receptors (PRRs) recognize pathogen and damage associated molecular patterns (DAMPs) during injury and achieve host defense directly. However, the role of NLR family CARD domain containing 5 (NLRC5), an important member of PPRs, beyond host defense in angiogenesis during tissue repair remains unknown. Methods:In vitro, western blot and real-time PCR (RT-PCR) were used to detect the expression of NLRC5 in endothelial cells (ECs). Immunofluorescence microscopy was used to reveal the subcellular location of NLRC5 in ECs. Cell proliferation, wound healing, tube formation assays of ECs were performed to study the role of NLRC5 in angiogenesis. By using Tie2Cre-NLRC5flox/flox mice and bone marrow transplantation studies, we defined an EC-specific role for NLRC5 in angiogenesis. Mechanistically, co-immunoprecipitation studies and RNA sequencing indicated that signal transducer and activator of transcription 3 (STAT3) was the target of NLRC5 in the nucleus. And Co-IP was used to verify the specific domain of NLRC5 binding with STAT3. ChIP assay determined the genes regulated by interaction of STAT3 and NLRC5. Results: Knockdown of NLRC5 in vitro or in vivo inhibited pathological angiogenesis, but had no effect on physiological angiogenesis. NLRC5 was also identified to bind to STAT3 in the nucleus required the integrated death-domain and nucleotide-binding domain (DD+NACHT domain) of NLRC5. And the interaction of STAT3 and NLRC5 could enhance the transcription of angiopoietin-2 (Ang2) and cyclin D1 (CCND1) to participate in angiogenesis. Conclusions: In the ischemic microenvironment, NLRC5 protein accumulates in the nucleus of ECs and enhances STAT3 transcriptional activity for angiogenesis. These findings establish NLRC5 as a novel modulator of VEGFA signaling, providing a new target for angiogenic therapy to foster tissue regeneration.
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma
Authors: Qingzhu Jia, Diyuan Qin, Feng He, Qichao Xie, Zhitao Ying, Yajing Zhang, Yuqin Song, Jia-Nan Cheng, Xuejiao Zuo, Luxiang Xu, Hongliang Fang, Chunyan Hu, Lina Peng, Tao Jin, Zixiao Shi, Peter B. Alexander, Yongsheng Wang, Yarong Liu, Weidong Han, Jun Zhu, Pin Wang, Qi-Jing Li, Bo Zhu
Journal: Theranostics (2021)

Rationale: The onset of cytokine release syndrome (CRS) and in vivo persistence of anti-CD19 chimeric antigen receptor T (CAR-T) cells after infusion correlate with clinical responsiveness. However, there are no known baseline biomarkers that can predict the prognosis of patients with B-lineage non-Hodgkin lymphoma (B-NHL). The aim of this study was to identify blood cell populations associated with beneficial outcomes in B-NHL patients administered CAR-T cell immunotherapies. Methods: We enumerated peripheral blood and CAR-T cells by retrospectively analyzing three CAR-T cell trials involving 65 B-NHL patients. We used a preclinical model to elucidate the eosinophil mechanism in CAR-T cell therapy. Results: During an observation period up to 30 mo, B-NHL patients with higher baseline eosinophil counts had higher objective response rates than those with low eosinophil counts. Higher baseline eosinophil counts were also significantly associated with durable progression-free survival (PFS). The predictive significance of baseline eosinophil counts was validated in two independent cohorts. A preclinical model showed that eosinophil depletion impairs the intratumoral infiltration of transferred CAR-T cells and reduces CAR-T cell antitumor efficacy. Conclusion: The results of this study suggest that peripheral eosinophils could serve as stratification biomarkers and a recruitment machinery to facilitate anti-CD19 CAR-T cell therapy in B-NHL patients.
10 years of the Syrian conflict: a time to act and not merely to remember
Authors: Samer Jabbour, Jennifer Leaning, Iman Nuwayhid, Alastair Ager, Melani Cammett, Omar Dewachi, Fouad M Fouad, Rita Giacaman, Debarati Guha Sapir, Ghassan Hage, Ziad Majed, Rabie Nasser, Annie Sparrow, Paul Spiegel, Ahmad Tarakji, Sarah Leah Whitson, Nasser Yassin
Journal: The Lancet (2021)
Association of Preterm Birth Rate With COVID-19 Statewide Stay-at-Home Orders in Tennessee
Authors: Elizabeth M. Harvey, Elizabeth McNeer, Morgan F. McDonald, Carrie K. Shapiro-Mendoza, William D. Dupont, Wanda Barfield, Stephen W. Patrick
Journal: JAMA Pediatrics (2021)

Association of Preterm Birth Rate With COVID-19 Statewide Stay-at-Home Orders in TennesseeTennessee identified its first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on March 4, 2020.Statewide stay-at-home orders were announced on March 22 and expired on April 30. 1 Recent studies have examined adverse pregnancy outcomes among women with SARS-CoV-2 infection. 2However, the literature examining the association of stay-at-home orders in response to coronavirus disease 2019 (COVID-19) with birth outcomes is sparse. 3Infants born preterm (less than 37 weeks' gestation) generally have higher morbidity and mortality risks than infants born at term (37 weeks' gestation or more). 4We examined the odds of preterm birth in Tennessee during the 2020 stay-at-home order compared with the same periods in 2015 to 2019.Methods | We used Tennessee birth records from 2015 to 2020 (2019 and 2020 were provisional data) for births among state residents.To account for seasonality, we restricted analyses to March 22 to April 30 for each year.Gestational ages less than 17 weeks or greater than 47 weeks were excluded (171 of 50 016 [0.3%]), yielding a total sample of 49 845 births.The Tennessee Department of Health Institutional Review Board determined this study met the requirements of public health surveillance and waived informed consent.The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.The preterm birth rate was based on the obstetric estimate of gestation 4 and calculated as the number of preterm births per 100 total births.Descriptive statistics were calculated, and logistic regression models were created comparing differences in the birth cohorts.Analyses were conducted using SAS version 9.4 (SAS Institute, Inc) and Stata version 14 (Stata-Corp).Two-tailed χ 2 tests were conducted, and P values < .05were considered statistically significant.
QIM21-084: Perceived Needs and Patient Satisfaction of Psychosocial Distress Screening and Management in Inpatient Hematology Oncology Specialty Care
Authors: Chao-Hui Sylvia Huang, Jennifer K. Anderson, Jasmine A. Boykin, Jasmine K. Vickers, Heather Forbes, Kellie L. Flood, Lisle M. Nabell, Kelly N. Godby
Journal: Journal of the National Comprehensive Cancer Network (2021)

"QIM21-084: Perceived Needs and Patient Satisfaction of Psychosocial Distress Screening and Management in Inpatient Hematology Oncology Specialty Care" published on 17 Mar 2021 by National Comprehensive Cancer Network.
Alcohol-Related Deaths in Poland During a Period of Weakening Alcohol Control Measures
Authors: Witold A. Zatonski, Mateusz Zatonski, Kinga Janik-Koncewicz, Andrzej Wojtyla
Journal: JAMA (2021)

This population epidemiology study describes trends in overall and age- and sex-specific alcohol-related deaths in Poland between 2002 and 2017, following the weakening in 2001 of policy measures designed to reduce alchohol consumption.
Trio cooperates with Myh9 to regulate neural crest-derived craniofacial development
Authors: Shuyu Guo, Li Meng, Haojie Liu, Lichan Yuan, Na Zhao, Jieli Ni, Yang Zhang, Jingjing Ben, Yi-Ping Li, Junqing Ma
Journal: Theranostics (2021)

Trio is a unique member of the Rho-GEF family that has three catalytic domains and is vital for various cellular processes in both physiological and developmental settings. TRIO mutations in humans are involved in craniofacial abnormalities, in which patients present with mandibular retrusion. However, little is known about the molecular mechanisms of Trio in neural crest cell (NCC)-derived craniofacial development, and there is still a lack of direct evidence to assign a functional role to Trio in NCC-induced craniofacial abnormalities. Methods:In vivo, we used zebrafish and NCC-specific knockout mouse models to investigate the phenotype and dynamics of NCC development in Trio morphants. In vitro, iTRAQ, GST pull-down assays, and proximity ligation assay (PLA) were used to explore the role of Trio and its potential downstream mediators in NCC migration and differentiation. Results: In zebrafish and mouse models, disruption of Trio elicited a migration deficit and impaired the differentiation of NCC derivatives, leading to craniofacial growth deficiency and mandibular retrusion. Moreover, Trio positively regulated Myh9 expression and directly interacted with Myh9 to coregulate downstream cellular signaling in NCCs. We further demonstrated that disruption of Trio or Myh9 inhibited Rac1 and Cdc42 activity, specifically affecting the nuclear export of β-catenin and NCC polarization. Remarkably, craniofacial abnormalities caused by trio deficiency in zebrafish could be partially rescued by the injection of mRNA encoding myh9, ca-Rac1, or ca-Cdc42. Conclusions: Here, we identified that Trio, interacting mostly with Myh9, acts as a key regulator of NCC migration and differentiation during craniofacial development. Our results indicate that trio morphant zebrafish and Wnt1-cre;Triofl/fl mice offer potential model systems to facilitate the study of the pathogenic mechanisms of Trio mutations causing craniofacial abnormalities.
MA09.08 Improving Overall Survival in Non-Small Cell Lung Cancer by Reducing R-Uncertain Resections With a Lymph Node Specimen Collection Kit
Authors: M. Smeltzer, N. Faris, Y. Lee, C. Fehnel, O. Akinbobola, C. Jones, M. Meadows-Taylor, A. Saulsberry, H. Dox, R. Eubanks, G. Valaulikar, D. Talton, B. Wolf, H. Wiggins, E. Sievers, P. Levy, E. Robbins, M. Ray, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2021)
Opportunities and challenges of three-dimensional printing technology in pharmaceutical formulation development
Authors: Mengsuo Cui, Hao Pan, Yupei Su, Dongyang Fang, Sen Qiao, Pingtian Ding, Weisan Pan
Journal: Acta Pharmaceutica Sinica B (2021)

Three-dimensional printing is a technology that prints the products layer-by-layer, in which materials are deposited according to the digital model designed by computer aided design (CAD) software. This technology has competitive advantages regarding product design complexity, product personalization, and on-demand manufacturing. The emergence of 3D technology provides innovative strategies and new ways to develop novel drug delivery systems. This review summarizes the application of 3D printing technologies in the pharmaceutical field, with an emphasis on the advantages of 3D printing technologies for achieving rapid drug delivery, personalized drug delivery, compound drug delivery and customized drug delivery. In addition, this article illustrates the limitations and challenges of 3D printing technologies in the field of pharmaceutical formulation development.
Spontaneous Coronary Artery Dissection and Cardiogenic Shock
Authors: Cathevine Yang, Taku Inohara, Mesfer Alfadhel, Cameron McAlister, Andrew Starovoytov, Dexter Choi, G.B. John Mancini, Eve Aymong, Jacqueline Saw
Journal: Journal of the American College of Cardiology (2021)
Benralizumab restores gene and microRNA expression involved in steroid sensitivity in severe asthma
Authors: Keita Hirai, Sekiko Uehara, Toshihiro Shirai, Yuuka Rachi, Tomoki Kimura, Taisuke Akamatsu, Kunihiko Itoh
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Biomaterial-based strategies for maxillofacial tumour therapy and bone defect regeneration
Authors: Bowen Tan, Quan Tang, Yongjin Zhong, Yali Wei, Linfeng He, Yanting Wu, Jiabao Wu, Jinfeng Liao
Journal: International Journal of Oral Science (2021)

Issues caused by maxillofacial tumours involve not only dealing with tumours but also repairing jaw bone defects. In traditional tumour therapy, the systemic toxicity of chemotherapeutic drugs, invasive surgical resection, intractable tumour recurrence, and metastasis are major threats to the patients' lives in the clinic. Fortunately, biomaterial-based intervention can improve the efficiency of tumour treatment and decrease the possibility of recurrence and metastasis, suggesting new promising antitumour therapies. In addition, maxillofacial bone tissue defects caused by tumours and their treatment can negatively affect the physiological and psychological health of patients, and investment in treatment can result in a multitude of burdens to society. Biomaterials are promising options because they have good biocompatibility and bioactive properties for stimulation of bone regeneration. More interestingly, an integrated material regimen that combines tumour therapy with bone repair is a promising treatment option. Herein, we summarized traditional and biomaterial-mediated maxillofacial tumour treatments and analysed biomaterials for bone defect repair. Furthermore, we proposed a promising and superior design of dual-functional biomaterials for simultaneous tumour therapy and bone regeneration to provide a new strategy for managing maxillofacial tumours and improve the quality of life of patients in the future.
P42.01 AI Assistance for Pulmonary Nodule Stratification: An Multiple-Reader Multiple-Case Study
Authors: E. O'Dowd, C. Bellinger, T. Dotson, C. Filippini, L. Pickup, Q. Chometon, C. Arteta, J. Declerck, T. Kadir, L. Freitag, A. Vachani, P. Massion, F. Gleeson, R. Munden, D. Baldwin
Journal: Journal of Thoracic Oncology (2021)